Neuropathology of patients with COVID-19 in Germany: a post-mortem case series.
Journal
The Lancet. Neurology
ISSN: 1474-4465
Titre abrégé: Lancet Neurol
Pays: England
ID NLM: 101139309
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
25
05
2020
revised:
14
08
2020
accepted:
19
08
2020
pubmed:
9
10
2020
medline:
4
11
2020
entrez:
8
10
2020
Statut:
ppublish
Résumé
Prominent clinical symptoms of COVID-19 include CNS manifestations. However, it is unclear whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, gains access to the CNS and whether it causes neuropathological changes. We investigated the brain tissue of patients who died from COVID-19 for glial responses, inflammatory changes, and the presence of SARS-CoV-2 in the CNS. In this post-mortem case series, we investigated the neuropathological features in the brains of patients who died between March 13 and April 24, 2020, in Hamburg, Germany. Inclusion criteria comprised a positive test for SARS-CoV-2 by quantitative RT-PCR (qRT-PCR) and availability of adequate samples. We did a neuropathological workup including histological staining and immunohistochemical staining for activated astrocytes, activated microglia, and cytotoxic T lymphocytes in the olfactory bulb, basal ganglia, brainstem, and cerebellum. Additionally, we investigated the presence and localisation of SARS-CoV-2 by qRT-PCR and by immunohistochemistry in selected patients and brain regions. 43 patients were included in our study. Patients died in hospitals, nursing homes, or at home, and were aged between 51 years and 94 years (median 76 years [IQR 70-86]). We detected fresh territorial ischaemic lesions in six (14%) patients. 37 (86%) patients had astrogliosis in all assessed regions. Activation of microglia and infiltration by cytotoxic T lymphocytes was most pronounced in the brainstem and cerebellum, and meningeal cytotoxic T lymphocyte infiltration was seen in 34 (79%) patients. SARS-CoV-2 could be detected in the brains of 21 (53%) of 40 examined patients, with SARS-CoV-2 viral proteins found in cranial nerves originating from the lower brainstem and in isolated cells of the brainstem. The presence of SARS-CoV-2 in the CNS was not associated with the severity of neuropathological changes. In general, neuropathological changes in patients with COVID-19 seem to be mild, with pronounced neuroinflammatory changes in the brainstem being the most common finding. There was no evidence for CNS damage directly caused by SARS-CoV-2. The generalisability of these findings needs to be validated in future studies as the number of cases and availability of clinical data were low and no age-matched and sex-matched controls were included. German Research Foundation, Federal State of Hamburg, EU (eRARE), German Center for Infection Research (DZIF).
Sections du résumé
BACKGROUND
Prominent clinical symptoms of COVID-19 include CNS manifestations. However, it is unclear whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, gains access to the CNS and whether it causes neuropathological changes. We investigated the brain tissue of patients who died from COVID-19 for glial responses, inflammatory changes, and the presence of SARS-CoV-2 in the CNS.
METHODS
In this post-mortem case series, we investigated the neuropathological features in the brains of patients who died between March 13 and April 24, 2020, in Hamburg, Germany. Inclusion criteria comprised a positive test for SARS-CoV-2 by quantitative RT-PCR (qRT-PCR) and availability of adequate samples. We did a neuropathological workup including histological staining and immunohistochemical staining for activated astrocytes, activated microglia, and cytotoxic T lymphocytes in the olfactory bulb, basal ganglia, brainstem, and cerebellum. Additionally, we investigated the presence and localisation of SARS-CoV-2 by qRT-PCR and by immunohistochemistry in selected patients and brain regions.
FINDINGS
43 patients were included in our study. Patients died in hospitals, nursing homes, or at home, and were aged between 51 years and 94 years (median 76 years [IQR 70-86]). We detected fresh territorial ischaemic lesions in six (14%) patients. 37 (86%) patients had astrogliosis in all assessed regions. Activation of microglia and infiltration by cytotoxic T lymphocytes was most pronounced in the brainstem and cerebellum, and meningeal cytotoxic T lymphocyte infiltration was seen in 34 (79%) patients. SARS-CoV-2 could be detected in the brains of 21 (53%) of 40 examined patients, with SARS-CoV-2 viral proteins found in cranial nerves originating from the lower brainstem and in isolated cells of the brainstem. The presence of SARS-CoV-2 in the CNS was not associated with the severity of neuropathological changes.
INTERPRETATION
In general, neuropathological changes in patients with COVID-19 seem to be mild, with pronounced neuroinflammatory changes in the brainstem being the most common finding. There was no evidence for CNS damage directly caused by SARS-CoV-2. The generalisability of these findings needs to be validated in future studies as the number of cases and availability of clinical data were low and no age-matched and sex-matched controls were included.
FUNDING
German Research Foundation, Federal State of Hamburg, EU (eRARE), German Center for Infection Research (DZIF).
Identifiants
pubmed: 33031735
pii: S1474-4422(20)30308-2
doi: 10.1016/S1474-4422(20)30308-2
pmc: PMC7535629
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
919-929Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Références
Ann Intensive Care. 2018 Dec 20;8(1):129
pubmed: 30570687
Int J Legal Med. 2020 Jul;134(4):1275-1284
pubmed: 32500199
J Exp Med. 2005 Aug 1;202(3):415-24
pubmed: 16043521
JAMA. 2020 Jun 23;323(24):2518-2520
pubmed: 32437497
Ann Intern Med. 2020 Aug 18;173(4):268-277
pubmed: 32374815
Nat Commun. 2020 Jan 9;11(1):166
pubmed: 31919373
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Nucleic Acids Res. 2003 Oct 15;31(20):e122
pubmed: 14530455
N Engl J Med. 2020 May 14;382(20):e60
pubmed: 32343504
JAMA Neurol. 2020 Jun 1;77(6):683-690
pubmed: 32275288
Eur J Neurol. 2020 Sep;27(9):e43-e44
pubmed: 32383343
Am J Clin Pathol. 2020 May 5;153(6):725-733
pubmed: 32275742
Acta Neuropathol. 2020 Jul;140(1):1-6
pubmed: 32449057
J Med Virol. 2020 Jun;92(6):552-555
pubmed: 32104915
N Engl J Med. 2020 Aug 6;383(6):590-592
pubmed: 32402155
Trends Neurosci. 2020 Jun;43(6):355-357
pubmed: 32359765
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
Radiology. 2020 Aug;296(2):E119-E120
pubmed: 32228363
Lancet. 2020 Jun 20;395(10241):e109
pubmed: 32505222
Virus Res. 2014 Dec 19;194:145-58
pubmed: 25281913
N Engl J Med. 2020 Jun 4;382(23):2268-2270
pubmed: 32294339
N Engl J Med. 2020 Mar 19;382(12):1177-1179
pubmed: 32074444
Neurology. 2020 Aug 4;95(5):e601-e605
pubmed: 32303650
Acta Neuropathol. 2019 Apr;137(4):619-635
pubmed: 30663001
Int J Infect Dis. 2020 May;94:55-58
pubmed: 32251791
Science. 2020 May 29;368(6494):1012-1015
pubmed: 32303590
N Engl J Med. 2020 Jun 25;382(26):2574-2576
pubmed: 32302082
Proc Natl Acad Sci U S A. 2015 Jun 9;112(23):7285-90
pubmed: 26060301
N Engl J Med. 2020 Sep 3;383(10):989-992
pubmed: 32530583
Brain Pathol. 2020 Jul;30(4):729
pubmed: 32592310
Brain Behav Immun. 2020 Jul;87:149
pubmed: 32387508
Brain Pathol. 2017 Sep;27(5):629-644
pubmed: 28805002
Lancet Neurol. 2020 May;19(5):383-384
pubmed: 32246917
Euro Surveill. 2020 Mar;25(9):
pubmed: 32156329
Acta Neuropathol. 2016 Feb;131(2):159-184
pubmed: 26659576